Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2014

01-11-2014 | Article

Fecal microbiome analysis as a diagnostic test for diverticulitis

Authors: L. Daniels, A. E. Budding, N. de Korte, A. Eck, J. A. Bogaards, H. B. Stockmann, E. C. Consten, P. H. Savelkoul, M. A. Boermeester

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2014

Login to get access

Abstract

Disease-specific variations in intestinal microbiome composition have been found for a number of intestinal disorders, but little is known about diverticulitis. The purpose of this study was to compare the fecal microbiota of diverticulitis patients with control subjects from a general gastroenterological practice and to investigate the feasibility of predictive diagnostics based on complex microbiota data. Thirty-one patients with computed tomography (CT)-proven left-sided uncomplicated acute diverticulitis were included and compared with 25 control subjects evaluated for a range of gastrointestinal indications. A high-throughput polymerase chain reaction (PCR)-based profiling technique (IS-pro) was performed on DNA isolates from baseline fecal samples. Differences in bacterial phylum abundance and diversity (Shannon index) of the resulting profiles were assessed by conventional statistics. Dissimilarity in microbiome composition was analyzed with principal coordinate analysis (PCoA) based on cosine distance measures. To develop a prediction model for the diagnosis of diverticulitis, we used cross-validated partial least squares discriminant analysis (PLS-DA). Firmicutes/Bacteroidetes ratios and Proteobacteria load were comparable among patients and controls (p = 0.20). The Shannon index indicated a higher diversity in diverticulitis for Proteobacteria (p < 0.00002) and all phyla combined (p = 0.002). PCoA based on Proteobacteria profiles resulted in visually separate clusters of patients and controls. The diagnostic accuracy of the cross-validated PLS-DA regression model was 84 %. The most discriminative species derived largely from the family Enterobacteriaceae. Diverticulitis patients have a higher diversity of fecal microbiota than controls from a mixed population, with the phylum Proteobacteria defining the difference. The analysis of intestinal microbiota offers a novel way to diagnose diverticulitis.
Literature
1.
go back to reference Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef
2.
go back to reference Bäckhed F, Ding H, Wang T et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101:15718–15723PubMedCrossRefPubMedCentral Bäckhed F, Ding H, Wang T et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101:15718–15723PubMedCrossRefPubMedCentral
3.
go back to reference Stappenbeck TS, Hooper LV, Gordon JI (2002) Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 99:15451–15455PubMedCrossRefPubMedCentral Stappenbeck TS, Hooper LV, Gordon JI (2002) Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 99:15451–15455PubMedCrossRefPubMedCentral
5.
go back to reference Hooper LV, Macpherson AJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10:159–169PubMedCrossRef Hooper LV, Macpherson AJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10:159–169PubMedCrossRef
6.
go back to reference Clarridge JE 3rd (2004) Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev 17:840–862PubMedCrossRefPubMedCentral Clarridge JE 3rd (2004) Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev 17:840–862PubMedCrossRefPubMedCentral
7.
go back to reference Budding AE, Grasman ME, Lin F et al (2010) IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. FASEB J 24:4556–4564PubMedCrossRef Budding AE, Grasman ME, Lin F et al (2010) IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. FASEB J 24:4556–4564PubMedCrossRef
9.
go back to reference Dethlefsen L, Huse S, Sogin ML et al (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6:e280PubMedCrossRefPubMedCentral Dethlefsen L, Huse S, Sogin ML et al (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6:e280PubMedCrossRefPubMedCentral
10.
go back to reference Wang X, Heazlewood SP, Krause DO et al (2003) Molecular characterization of the microbial species that colonize human ileal and colonic mucosa by using 16S rDNA sequence analysis. J Appl Microbiol 95:508–520PubMedCrossRef Wang X, Heazlewood SP, Krause DO et al (2003) Molecular characterization of the microbial species that colonize human ileal and colonic mucosa by using 16S rDNA sequence analysis. J Appl Microbiol 95:508–520PubMedCrossRef
11.
go back to reference Zoetendal EG, Akkermans ADL, de Vos WM (1998) Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64:3854–3859PubMedPubMedCentral Zoetendal EG, Akkermans ADL, de Vos WM (1998) Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64:3854–3859PubMedPubMedCentral
13.
go back to reference Frank DN, St Amand AL, Feldman RA et al (2007) Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785PubMedCrossRefPubMedCentral Frank DN, St Amand AL, Feldman RA et al (2007) Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785PubMedCrossRefPubMedCentral
14.
go back to reference Zoetendal EG, von Wright A, Vilpponen-Salmela T et al (2002) Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68:3401–3407PubMedCrossRefPubMedCentral Zoetendal EG, von Wright A, Vilpponen-Salmela T et al (2002) Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68:3401–3407PubMedCrossRefPubMedCentral
15.
go back to reference Sokol H, Pigneur B, Watterlot L et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736PubMedCrossRefPubMedCentral Sokol H, Pigneur B, Watterlot L et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736PubMedCrossRefPubMedCentral
16.
go back to reference Swidsinski A, Loening-Baucke V, Vaneechoutte M et al (2008) Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 14:147–161PubMedCrossRef Swidsinski A, Loening-Baucke V, Vaneechoutte M et al (2008) Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 14:147–161PubMedCrossRef
17.
go back to reference Ley RE, Turnbaugh PJ, Klein S et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMedCrossRef Ley RE, Turnbaugh PJ, Klein S et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMedCrossRef
18.
go back to reference Turnbaugh PJ, Ley RE, Mahowald MA et al (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031PubMedCrossRef Turnbaugh PJ, Ley RE, Mahowald MA et al (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031PubMedCrossRef
19.
go back to reference Swidsinski A, Dörffel Y, Loening-Baucke V et al (2011) Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 60:34–40PubMedCrossRef Swidsinski A, Dörffel Y, Loening-Baucke V et al (2011) Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 60:34–40PubMedCrossRef
20.
go back to reference Floch MH (2006) A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol 40(Suppl 3):S121–S125PubMedCrossRef Floch MH (2006) A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol 40(Suppl 3):S121–S125PubMedCrossRef
22.
go back to reference Unlü C, de Korte N, Daniels L et al; Dutch Diverticular Disease 3D Collaborative Study Group (2010) A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). BMC Surg 10:23PubMedCrossRefPubMedCentral Unlü C, de Korte N, Daniels L et al; Dutch Diverticular Disease 3D Collaborative Study Group (2010) A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). BMC Surg 10:23PubMedCrossRefPubMedCentral
23.
go back to reference Wasvary H, Turfah F, Kadro O et al (1999) Same hospitalization resection for acute diverticulitis. Am Surg 65:632–635PubMed Wasvary H, Turfah F, Kadro O et al (1999) Same hospitalization resection for acute diverticulitis. Am Surg 65:632–635PubMed
25.
go back to reference Mendeloff AI (1986) Thoughts on the epidemiology of diverticular disease. Clin Gastroenterol 15:855–877PubMed Mendeloff AI (1986) Thoughts on the epidemiology of diverticular disease. Clin Gastroenterol 15:855–877PubMed
26.
go back to reference Syed SA, Loesche WJ (1972) Survival of human dental plaque flora in various transport media. Appl Microbiol 24:638–644PubMedPubMedCentral Syed SA, Loesche WJ (1972) Survival of human dental plaque flora in various transport media. Appl Microbiol 24:638–644PubMedPubMedCentral
28.
go back to reference Rajilić-Stojanović M, Biagi E, Heilig HG et al (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141:1792–1801PubMedCrossRef Rajilić-Stojanović M, Biagi E, Heilig HG et al (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141:1792–1801PubMedCrossRef
29.
go back to reference Hastie T, Tibshirani R, Friedman J (2001) The elements of statistical learning. Springer, New YorkCrossRef Hastie T, Tibshirani R, Friedman J (2001) The elements of statistical learning. Springer, New YorkCrossRef
30.
go back to reference Pérez-Enciso M, Tenenhaus M (2003) Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 112:581–592PubMed Pérez-Enciso M, Tenenhaus M (2003) Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 112:581–592PubMed
31.
go back to reference Nguyen DV, Rocke DM (2002) Tumor classification by partial least squares using microarray gene expression data. Bioinformatics 18:39–50PubMedCrossRef Nguyen DV, Rocke DM (2002) Tumor classification by partial least squares using microarray gene expression data. Bioinformatics 18:39–50PubMedCrossRef
32.
go back to reference Modlich O, Prisack HB, Munnes M et al (2005) Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 3:32PubMedCrossRefPubMedCentral Modlich O, Prisack HB, Munnes M et al (2005) Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 3:32PubMedCrossRefPubMedCentral
33.
go back to reference Diaz SO, Barros AS, Goodfellow BJ et al (2013) Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res 12:2946–2957PubMedCrossRef Diaz SO, Barros AS, Goodfellow BJ et al (2013) Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res 12:2946–2957PubMedCrossRef
34.
go back to reference Tap J, Mondot S, Levenez F et al (2009) Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 11:2574–2584PubMedCrossRef Tap J, Mondot S, Levenez F et al (2009) Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 11:2574–2584PubMedCrossRef
35.
go back to reference Brook I, Frazier EH (2000) Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 49:827–830PubMed Brook I, Frazier EH (2000) Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 49:827–830PubMed
36.
go back to reference Gueimonde M, Ouwehand A, Huhtinen H et al (2007) Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 13:3985–3989PubMedCrossRefPubMedCentral Gueimonde M, Ouwehand A, Huhtinen H et al (2007) Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 13:3985–3989PubMedCrossRefPubMedCentral
37.
go back to reference de Korte N, Unlü C, Boermeester MA et al (2011) Use of antibiotics in uncomplicated diverticulitis. Br J Surg 98:761–767PubMedCrossRef de Korte N, Unlü C, Boermeester MA et al (2011) Use of antibiotics in uncomplicated diverticulitis. Br J Surg 98:761–767PubMedCrossRef
38.
go back to reference Chabok A, Påhlman L, Hjern F et al; AVOD Study Group (2012) Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg 99:532–539PubMedCrossRef Chabok A, Påhlman L, Hjern F et al; AVOD Study Group (2012) Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg 99:532–539PubMedCrossRef
39.
go back to reference Colecchia A, Vestito A, Pasqui F et al (2007) Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 13:264–269PubMedCrossRefPubMedCentral Colecchia A, Vestito A, Pasqui F et al (2007) Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 13:264–269PubMedCrossRefPubMedCentral
40.
go back to reference Papi C, Ciaco A, Koch M et al (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 24:452–456PubMed Papi C, Ciaco A, Koch M et al (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 24:452–456PubMed
41.
go back to reference Latella G, Pimpo MT, Sottili S et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRef Latella G, Pimpo MT, Sottili S et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRef
42.
go back to reference Papi C, Ciaco A, Koch M et al (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33–39PubMedCrossRef Papi C, Ciaco A, Koch M et al (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33–39PubMedCrossRef
43.
go back to reference Porta E, Germano A, Ferrieri A et al (1994) The natural history of diverticular disease of the colon: A role for antibiotics in preventing complications? A retrospective study. Riv Eur Sci Med Farmacol 16:33–39PubMed Porta E, Germano A, Ferrieri A et al (1994) The natural history of diverticular disease of the colon: A role for antibiotics in preventing complications? A retrospective study. Riv Eur Sci Med Farmacol 16:33–39PubMed
44.
go back to reference Tursi A, Brandimarte G, Giorgetti GM et al (2007) Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 22:1103–1108PubMedCrossRef Tursi A, Brandimarte G, Giorgetti GM et al (2007) Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 22:1103–1108PubMedCrossRef
45.
go back to reference Dughera L, Serra AM, Battaglia E et al (2004) Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 50:149–153PubMed Dughera L, Serra AM, Battaglia E et al (2004) Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 50:149–153PubMed
46.
go back to reference Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef
47.
go back to reference Lamiki P, Tsuchiya J, Pathak S et al (2010) Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis 19:31–36PubMed Lamiki P, Tsuchiya J, Pathak S et al (2010) Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis 19:31–36PubMed
48.
go back to reference Laméris W, van Randen A, van Gulik TM et al (2010) A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 53:896–904PubMedCrossRef Laméris W, van Randen A, van Gulik TM et al (2010) A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 53:896–904PubMedCrossRef
Metadata
Title
Fecal microbiome analysis as a diagnostic test for diverticulitis
Authors
L. Daniels
A. E. Budding
N. de Korte
A. Eck
J. A. Bogaards
H. B. Stockmann
E. C. Consten
P. H. Savelkoul
M. A. Boermeester
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2014
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2162-3

Other articles of this Issue 11/2014

European Journal of Clinical Microbiology & Infectious Diseases 11/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.